#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Why Dying Liver Cells Drive MASH
A 2026 review explains how cell death fuels MASH, the liver disease semaglutide became the first FDA-approved drug to treat.
GLP-1 Drugs, PCOS, and Stopping Treatment
Some GLP-1 users say PCOS symptoms return after stopping treatment. Here is what the semaglutide and retatrutide trial data actually shows.
Semaglutide and tirzepatide for MASH
Semaglutide now has FDA approval for MASH liver fibrosis, and tirzepatide's phase 2 data suggests a stronger signal is coming.
GLP-1 Drugs and Skin Cancer Risk
A new Dermatologic Surgery paper links semaglutide and tirzepatide to lower skin cancer rates in patients with obesity, but the abstract isn't public yet.
Testing Tirzepatide After Gastric Bypass
A Vanderbilt pilot trial called GRABS is testing tirzepatide in patients whose obesity persists after gastric bypass surgery.
What Medicare's GLP-1 bridge may cost
CMS has disclosed Medicare's $50 GLP-1 copay and a manufacturer net price, but not a total taxpayer cost estimate.
Mwyngil's non-GLP-1 obesity approach
Mwyngil is pursuing GPR75 and NLRP3 pathways for obesity. The targets are interesting, but the program remains preclinical.
How to read an oral GLP-1 script tracker
A new tracker follows oral Wegovy and Foundayo prescriptions. Here is what script growth can show, and what it cannot.
Does tirzepatide cut carpal tunnel risk?
A 2026 cohort study links tirzepatide to fewer carpal tunnel diagnoses than other weight drugs. That is an association, not a treatment effect.
Why GLP-1 prescriptions go unfilled
About 40% of GLP-1 orders are never dispensed. Here is what the fill-rate evidence on semaglutide and tirzepatide shows, and what it cannot show.
Finding at-risk MASH without a liver biopsy
With semaglutide approved for MASH, finding the right patients is the bottleneck, and a new study says a liver stiffness scan can do it without a biopsy.
STEP 12: semaglutide in Chinese adults
STEP 12 tested semaglutide 2.4 mg in Chinese adults at a BMI of 24 to under 30, a band the earlier STEP obesity trials never enrolled.